CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the second quarter ended June 30, 2025. "We are exceeding many of our internal expectations," said Intellia President and Chief Executive Officer John Leonard, M.D. "The enthusiasm from both patients and physicians for Intellia's late-stage p ...